Eplerenone

Category: pharmacological

Aliases: Inspra

Pharmacological Mechanism

Selective mineralocorticoid receptor antagonist — fewer anti-androgenic / progestational side effects than spironolactone (no gynecomastia). Approved for HFrEF post-MI + resistant hypertension. Hyperkalemia risk; CYP3A4 substrate (avoid with strong inhibitors).

Half-Life (t½)

PO: 3h

Dosing Guidelines

• PO: Typical 50mg (Range: 25 - 50 mg)

Target Organ Systems

• cardiovascular
• endocrine
• digestive